SCHEMBL22734261

SCHEMBL22734261

Cc1cccc2[nH]cc(CC(NC(=O)OC(C)(C)C)C(=O)O)c12

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACE P12821 3/20 0.57
SCN9A Q15858 2/20 0.56
CTSL P07711 2/20 0.55
CTSS P25774 1/20 0.55
CTSK P43235 1/20 0.55
ITGB2 P05107 2/20 0.53
ICAM1 P05362 2/20 0.53
ITGAL P20701 2/20 0.53
MAPT P10636 3/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
TACR1 P25103 2/20 0.52
TP53 P04637 2/20 0.52
POLB P06746 2/20 0.52
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
SSTR3 P32745 1/20 0.48
ALOX15 P16050 1/20 0.46
KDM4E B2RXH2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22734260 1.00 ACE (0.57) ACESCN9ACTSLCTSSCTSK
SCHEMBL29843161 1.00 ACE (0.57) ACESCN9ACTSLCTSSCTSK
SCHEMBL31407359 0.88 ACE (0.56) ACESCN9ACTSLCTSSCTSK
SCHEMBL20738961 0.85 ACE (0.58) ACESCN9ACTSLCTSSCTSK
SCHEMBL20738963 0.85 ACE (0.58) ACESCN9ACTSLCTSSCTSK
SCHEMBL8187318 0.83 CTSL (0.54) CTSLCTSSCTSKMAPTSMN1; SMN2
SCHEMBL1486167 0.83 ACE (0.77) ACESCN9ACTSLCTSSCTSK
SCHEMBL850438 0.83 ACE (0.77) ACESCN9ACTSLCTSSCTSK
SCHEMBL30976323 0.83 ACE (0.77) ACESCN9ACTSLCTSSCTSK
SCHEMBL1003555 0.83 ACE (0.77) ACESCN9ACTSLCTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250325508-A1 MODULATORS OF PROTEASOME DYNAMICS AND/OR FUNCTION, COMPOSITIONS, METHODS, AND THERAPEUTIC USES THEREOF TECHNION RES & DEV FOUNDATION (IL) 2025-10-23 US disclosed
US-20240057599-A1 METHODS FOR IMPROVING FRUIT QUALITY THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI CENTER) (IL) 2024-02-22 US disclosed
CN-117062529-A Method for improving fruit quality 以色列农业和农村发展部农业研究组织(范卡尼研究所) 2023-11-14 CN disclosed
US-20230330064-A1 TYROSINE, TRYPTOPHAN AND PHENYLALANINE AS mTOR AGONISTS MEDIATING PROTEASOME DYNAMICS, COMPOSITIONS, METHODS AND USES THEREOF IN THERAPY, AND PROGNOSTIC METHODS FOR DRUG-RESISTANCE RAMBAM MED-TECH LTD. (IL) 2023-10-19 US disclosed
CN-115843565-A Method for improving plant performance 以色列农业和农村发展部农业研究组织(范卡尼中心) 2023-03-28 CN disclosed
CN-111988994-B Method for improving plant performance 以色列农业和农村发展部农业研究组织(范卡尼中心) 2023-01-10 CN disclosed
US-20200383327-A1 METHOD OF IMPROVING PLANT PERFORMANCE THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI CENTER) (IL) 2020-12-10 US disclosed
CN-111988994-A Method for improving plant performance 以色列农业和农村发展部农业研究组织(范卡尼中心) 2020-11-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230330064-A1 TYROSINE, TRYPTOPHAN AND PHENYLALANINE AS mTOR AGONISTS MEDIATING PROTEASOME DYNAMICS, COMPOSITIONS, METHODS AND USES THEREOF IN THERAPY, AND PROGNOSTIC METHODS FOR DRUG-RESISTANCE RPTOR, PSMG3, MTOR ACE 3535/4885SCN9A 4655/4885CTSL 2273/4885
US-20250325508-A1 MODULATORS OF PROTEASOME DYNAMICS AND/OR FUNCTION, COMPOSITIONS, METHODS, AND THERAPEUTIC USES THEREOF PSMC1, PSME3, PSMA6 ACE 3987/4885SCN9A 3990/4885CTSL 2871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.